Isis, Alnylam form RNAi company
DEALS |
|||
WHO |
WITH |
WHAT |
SCOOP |
Alpharma |
IDEA |
$202 licensing deal |
Alpharma has agreed to pay Germany's IDEA up to $202 million in upfront fees and milestones for the U.S. rights to the late-stage pain drug Diractin, a prescription topical NSAID. |
Nabi Biopharmaceuticals |
Biotest |
$185M sale |
Nabi Biopharmaceuticals plans to sell its biologics unit to Germany's Biotest for $185 million. |
Boehringer Ingelheim |
Ablynx |
$103.5M partnership |
Boehringer has signed a second agreement with Ablynx to develop and commercialize up to 10 different Nanobody therapeutics. |
Medivation |
Azimuth Opportunity |
$100M stock deal |
VC firm Azimuth Opportunity will purchase $100 million of Medivation's stock over the next 18 months as the drug developer pushes through a late-stage trial of an experimental Alzheimer's drug. |
Meda |
BioDelivery Sciences |
$90M licensing deal |
Meda will pay BioDelivery up to $90 million in exchange for a licensing deal covering the North American rights to BEMA Fentanyl, a new pain patch for cancer patients. |
Ventana Medical Systems |
Spring BioScience |
$31M acquisition |
Ventana Medical Systems has inked a deal to acquire Spring BioScience, which makes rabbit monoclonal antibodies and other reagents. |
Isis Pharmaceuticals |
Alnylam Pharmaceuticals |
Company formation |
Isis and Alnylam have teamed up to form Regulus Therapeutics, a company that will focus on developing new drugs based on micro-RNA. |